These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
9. Consolidations in biotechnology. Persidis A Nat Biotechnol; 1999 Feb; 17 Suppl():BE3-4. PubMed ID: 10052311 [No Abstract] [Full Text] [Related]
10. The changing attitude of European VCs. Mitchell P Nat Biotechnol; 2004 Apr; 22(4):479. PubMed ID: 15085807 [No Abstract] [Full Text] [Related]
11. The rise of European venture capital for biotechnology. Howell M; Trull M; Dibner MD Nat Biotechnol; 2003 Nov; 21(11):1287-91. PubMed ID: 14595356 [No Abstract] [Full Text] [Related]
12. Partnering up in Q3. Lawrence S Nat Biotechnol; 2007 Nov; 25(11):1200. PubMed ID: 17989659 [No Abstract] [Full Text] [Related]
13. Biotechnology financing dilemmas and the role of special purpose entities. Schiff L; Murray F Nat Biotechnol; 2004 Mar; 22(3):271-7. PubMed ID: 14990945 [No Abstract] [Full Text] [Related]
14. This means war. Nat Biotechnol; 2008 Sep; 26(9):954. PubMed ID: 18779784 [TBL] [Abstract][Full Text] [Related]
15. Strategic consolidation: the biotechnology business model for the 21st century. Esposito RS; Ostro MJ Nat Biotechnol; 1999 Feb; 17 Suppl():BE16-7. PubMed ID: 10052317 [No Abstract] [Full Text] [Related]
16. Gold in the ivory tower: equity rewards of outlicensing. Edwards M; Murray F; Yu R Nat Biotechnol; 2006 May; 24(5):509-15. PubMed ID: 16680129 [TBL] [Abstract][Full Text] [Related]